#None #securities lawsuit #DJS Law Group #Capricor Therapeutics

Capricor Therapeutics in Legal Trouble: A Class Action Overview

Capricor Therapeutics, Inc. is currently embroiled in a class action lawsuit that has raised concerns among its investors. The suit alleges that the company violated the Securities Exchange Act, specifically citing provisions under §§10(b) and 20(a). Investors who purchased shares during the specified class period are being encouraged to take action and explore their rights through the DJS Law Group.

Background on Capricor’s Allegations

The lawsuit centers around Capricor's alleged misrepresentation of facts to the market. Specifically, it has been claimed that the company altered its statistical analysis plan related to clinical data for its leading therapy, Deramiocel. One of the key issues identified is that Capricor reportedly did not secure prior agreement from the FDA regarding this change before resubmitting a crucial Biologics License Application for the drug, leading to public statements that were deemed materially misleading throughout the class action period, which extends from December 17, 2025, to July 26, 2026.

With a deadline for class action participation set for September 28, 2026, shareholders who are affected and have suffered losses during this timeframe are encouraged to reach out to the DJS Law Group for potential lead plaintiff opportunities. It's important to note that becoming a lead plaintiff is not a prerequisite for participating in any recovery.

Why Consider Joining the Case?

The DJS Law Group, which is spearheading this case, has a solid reputation for advocating for investor rights. They emphasize a balanced approach to legal strategies, utilizing aggressive advocacy to maximize investor returns. David Schwartz, one of the founding partners of the firm, has extensive experience handling securities class actions and firmly believes that every investor deserves respect and recognition for their claims, particularly in complex cases involving corporate governance litigation.

What Should Investors Do?

Investors who are shareholders of Capricor Therapeutics and are concerned about their rights need to act swiftly. The potential for recovering losses hinges on timely participation in the class action. If you’ve suffered as a result of perceived mismanagement or misinformation from the company, consulting with legal professionals adept in securities law may prove beneficial. Understanding the changing landscape of securities regulations and how they might impact investments is crucial in today’s market.

Investors should also stay informed about the developments in the lawsuit as allegations unfold. Engaging with legal counsel can provide insights into what these legal troubles could imply for the future of Capricor and their investments.

Conclusion

Capricor Therapeutics is facing a significant challenge as a class action lawsuit unfolds, raising critical questions about its compliance with securities laws and overall corporate transparency. Investors should take heed of this legal action, understand their rights, and consider participation if they believe they have been wronged during the class period. Having strong legal representation, such as that offered by the DJS Law Group, can make a substantial difference in navigating these difficult waters effectively.